



1 Supplementary Figures



- 2 Figure S1. Evaluation of inflammation in lung and liver after NCD oral administration. (A-D) The
- 3 lungs, and liver of the three groups (sham, DMM, and DMM+NCD 50 mg/kg) were stained to
- 4 examine histological characteristics (n = 5 mice/group) to evaluate the inflammation caused by long-
- 5 term oral administration of NCD. The images of the lung and liver were captured under the
- 6 microscope at $100 \times$. Scale bar = 100μ m. Sham: control. Values were assessed using the Kruskal-
- 7 Wallis and Dunn's tests.

8



- 9 Figure S2. Evaluation of inflammation in lung and liver after intra articular injection of NCD. (A-D)
- 10 The lungs, and liver of the three groups (sham, DMM, and DMM+NCD 50 µg) were stained to
- 11 examine histological characteristics (n = 5 mice/group) to evaluate the inflammation caused by intra
- 12 articular injection of NCD. The images of the lung and liver were captured under the microscope at
- 13 $100 \times$. Scale bar = 100 μ m. Sham: control. Values were assessed using the Kruskal-Wallis and
- 14 Dunn's tests. n.s., not significant.

15

16 Supplementary table

NCD —	Dose (mg/kg)		
	5	10	20
Cmax (ng/ml)	1111.52	2559.25	4150.81
Half-life (hour)	0.41	0.59	0.76
AUC0-t (ng·hr/mL)	631.83	1728.88	4526.66

17 Table 1. Pharmacokinetic Parameters of NCD Following Intravenous Administration in SD Rats

18

19